WallStSmart

Monte Rosa Therapeutics Inc (GLUE)vsModerna Inc (MRNA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 3490% more annual revenue ($2.52B vs $70.33M). MRNA leads profitability with a -110.5% profit margin vs -186.2%. GLUE earns a higher WallStSmart Score of 36/100 (F).

GLUE

Hold

36

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: 0.02

MRNA

Avoid

31

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GLUE.

MRNAUndervalued (+73.2%)

Margin of Safety

+73.2%

Fair Value

$150.95

Current Price

$195.00

$44.05 discount

UndervaluedFair: $150.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GLUE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
325.8%10/10

Revenue surging 325.8% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

MRNA2 strengths · Avg: 8.5/10
Market CapQuality
$101.49B9/10

Large-cap with strong market position

Revenue GrowthGrowth
29.2%8/10

Revenue surging 29.2% year-over-year

Areas to Watch

GLUE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$880.99M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-26.4%2/10

ROE of -26.4% — below average capital efficiency

Free Cash FlowQuality
$-42.54M2/10

Negative free cash flow — burning cash

MRNA4 concerns · Avg: 2.8/10
Price/BookValuation
11.5x4/10

Trading at 11.5x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-40.8%2/10

ROE of -40.8% — below average capital efficiency

EPS GrowthGrowth
-85.1%2/10

Earnings declined 85.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : GLUE

The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.

Bear Case : GLUE

The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

GLUE profiles as a hypergrowth stock while MRNA is a growth play — different risk/reward profiles.

GLUE carries more volatility with a beta of 1.38 — expect wider price swings.

GLUE is growing revenue faster at 325.8% — sustainability is the question.

GLUE generates stronger free cash flow (-43M), providing more financial flexibility.

Bottom Line

GLUE scores higher overall (36/100 vs 31/100) and 325.8% revenue growth. MRNA offers better value entry with a 73.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monte Rosa Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.

Visit Website →

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?